MyAverix Finance MyAverix Finance

LSE

Supernus Pharmaceuticals, Inc. (0LB2)

Supernus Pharmaceuticals, Inc. (0LB2) is listed on LSE. As of 2026-05-23, reported P/E ratio is 18.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Data as of 2026-05-23

Download on the App Store Get it on Google Play

Download free on iPhone and Android

Key metrics for 0LB2

P/E ratio
18.00

Supernus Pharmaceuticals, Inc. (0LB2) — FAQ

What is 0LB2's P/E ratio?

The price-to-earnings (P/E) ratio for Supernus Pharmaceuticals, Inc. (0LB2) is 18.00 (data as of 2026-05-23).

Does Supernus Pharmaceuticals, Inc. pay a dividend?

Dividend yield is not available in the current snapshot for Supernus Pharmaceuticals, Inc. (0LB2). Check the MyAverix Finance app for the latest dividend data.

What exchange is 0LB2 listed on?

0LB2 is listed on LSE.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

← All stocks

MyAverix Finance provides company information and financial data for educational and research purposes only. We are not a broker, advisor, or investment service. Data may be delayed or incomplete. Past performance does not guarantee future results. Always do your own research before making financial decisions.

Terms of Use

App Store Google Play